Project description
Tumour cells, tumour microenvironment and immune system interplay
Cancer progression is a complex process that depends on the interplay between tumour cells, tumour microenvironment and the immune system. In order to better understand tumour biology and response to treatment, it is necessary to profile protein expression of the whole interconnected system. Multiplexed ion beam imaging by time of flight (MIBI-TOF) is a technology in which antibodies conjugated to metals are used to simultaneously visualise dozens of proteins in intact tissue samples by secondary ion mass spectrometry. The EU-funded MelImmuneOrg project aims to uncover the immune profile and organisation within the tumours of melanoma patients undergoing immunotherapy using MIBI-TOF. The objectives are to analyse the intratumour heterogeneity and the genetic correlations between tumour, immune microenvironment and response to therapy.
Objective
Cancer progression is a complex process that depends on the interplay between tumor cells, tumor microenvironment, and the immune system. Inhibiting immunosuppression is beneficial for cancer patients. Although these therapies are promising they are successful only in part of the patients. Tumors are composed of distinct cell types with different phenotypes, that influence the efficacy of immunotherapies. Therefore, in order to better understand tumor biology and response to treatment, it is necessary to profile protein expression while preserving spatial information. Multiplexed Ion Beam Imaging by Time of Flight (MIBI-TOF) is a method in which antibodies conjugated to metals are used to simultaneously visualize dozens of proteins in intact tissue specimens by secondary ion mass spectrometry. Here we suggest to uncover the immune profile and organization within the tumors of melanoma patients undergoing immunotherapy using MIBI-TOF. My first objective is to characterize the tumor-immune microenvironments to understand how these are structured across patients and discover predictive features of response to immunotherapies. My second objective is to analyze the intratumor heterogeneity (ITH) of melanoma patients by exome sequencing. I will examine whether there are genetic correlates between ITH, immune microenvironment and response to therapy. Finally, my third objective will be the manipulation of individual hits to test their functional significance in tumor-immune architecture in murine models. By joining Dr. Keren’s lab that masters the MIBI-TOF technology, I will acquire this state-of-the art technique, as well as develop lab management and organization skills, and I will meet leader scientists from the immune-oncology field. This proposal will promote my competitiveness to gain an independent researcher position.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology skin cancer melanoma
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology immunotherapy
- natural sciences chemical sciences analytical chemistry mass spectrometry
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
7610001 Rehovot
Israel
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.